Previously, GLP-1 medications which mimic the naturally occurring hormone glucagon-like peptide-1, which regulates blood sugar, digestion, and hunger had been approved only to treat obesity in the form of weekly, home-administered injections
Clinically, IGF-1 and derivatives are used to treat patients who suffer from muscle wasting due to conditions like HIV, as well as patients with hormonal disorders [2]
Once-daily oral GLP-1 receptor agonist Can be taken with or without food or water Helps reduce appetite and supports blood sugar control A convenient alternative for those who prefer tablets over injections Indications: Obesity Overweight with comorbidities such as Type 2 Diabetes or hypertension Common side effects: Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and headache
Finally, most of the trials were not long enough to comply with the FDA recommendations regarding cardiovascular outcomes [24]
Employers have a real opportunity to step in, offer these treatments affordably and with dignity, and position themselves as employers of choice. While weighing the choice to cover GLP-1s, employer cost is a significant consideration, Midlam noted